Received: 24 April 2020
Accepted: 29 June 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: The SPICE III trial complied with the Declaration of Helsinki and Good Clinical Practices and was approved by the institutional review board at participating centers. Written informed consent was obtained for all patients. The present subgroup analysis was performed at the Austin Hospital, Melbourne, Australia, and the University Hospital of Bern, Switzerland, and was approved by the ethics committees at both sites (approval number LNR/15/Austin/391 and KEK-ID2018-00746).
: Not applicable.
: Dr. Shehabi reports receiving travel support and lecture fees, paid to Monash Health, and lecture fees from Pfizer (Malaysia) and Orion Pharma and fees for expert testimony from Stephens Lawyers and Consultants, Melbourne; Dr. Bellomo, receiving fees for expert testimony from Pfizer; and Dr. Takala, receiving consulting fees from Nestec. The Department of Intensive Care Medicine (Inselspital), Bern University Hospital has, or has had in the past, research contracts with Abionic SA, AVA AG, CSEM SA, Cube Dx GmbH, Cyto Sorbents Europe GmbH, Edwards Lifesciences LLC, GE Healthcare, ImaCor Inc., MedImmune LLC, Orion Corporation, Phagenesis Ltd. and research and development/consulting contracts with Edwards Lifesciences LLC, Nestec SA, Wyss Zurich. The money was paid into a departmental fund; the investigators received no personal financial gain.